GDOC Goldman Sachs Future Health Care Equity ETF

ETF on NYSE (US) · Actively managed · Listing

Form N-PORT Aug 31, 2026 vs May 31, 2026 Filed with the SEC Oct 27, 2026
Book −2% $20.1M → $19.7M
Line items (May 31, 2026: 42) 41
In top 10 57%
Largest holding: Eli Lilly and Company ($2.39M) 12.1%
Portfolio date Aug 31, 2026
New / increased 3 / 12
Reduced / closed 24 / 5
Unchanged 0
−40%

Most notable sale · Guardant Health, Inc.

Guardant Health, Inc. cut by 40%

Shares went from 8,286 to 4,952 ($1.07M → $787K). Now 4.0% of the portfolio. Estimated trade $530K.

4.1x

Most notable buy · UnitedHealth Group Incorporated

UnitedHealth Group Incorporated raised 4.1x

Shares went from 715 to 2,912 ($272K → $1.13M). Now 5.8% of the portfolio. Estimated trade $856K.

Largest holding: Eli Lilly and Company, cut 15%, 2,066 shares ($2.39M).

Eli Lilly and Company: 12.1% Johnson & Johnson: 8.3% Merck & Company, Inc.: 7.4% UnitedHealth Group Incorporated: 5.8% Vertex Pharmaceuticals Incorporated: 4.2% argenx SE: 4.1% Guardant Health, Inc.: 4.0% DexCom, Inc.: 3.8% Agilent Technologies, Inc.: 3.5% Thermo Fisher Scientific Inc: 3.5% The other 31 positions: 43.3% $19.7M Holdings value
Current positions Top 10 % of book
Eli Lilly and Company LLY $2.39M · −15% sh 12.1%
Johnson & Johnson JNJ $1.63M · −15% sh 8.3%
Merck & Company, Inc. MRK $1.46M · −2% sh 7.4%
UnitedHealth Group Incorporated UNH $1.13M · 4.1x sh 5.8%
Vertex Pharmaceuticals Incorporated VRTX $823K · 2.3x sh 4.2%
argenx SE ARGX $812K · −20% sh 4.1%
Guardant Health, Inc. GH $787K · −40% sh 4.0%
DexCom, Inc. DXCM $757K · +9% sh 3.8%
Agilent Technologies, Inc. A $689K · +9% sh 3.5%
Thermo Fisher Scientific Inc TMO $687K · −40% sh 3.5%

Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against May 31, 2026.

Healthcare: 93.1% Financial Services: 1.7% Technology: 1.7% Unclassified: 3.5% 3 sectors
Sectors % of holdings value
Healthcare 93.1%
Financial Services 1.7%
Technology 1.7%
Unclassified 3.5%
Drug Manufacturers - General: 29.8% Biotechnology: 23.8% Medical Devices: 13.8% Medical Instruments & Supplies: 7.5% Diagnostics & Research: 6.9% Healthcare Plans: 5.8% Drug Manufacturers - Specialty & Generic: 2.8% Other (3): 6.1% Unclassified: 3.5% 10 industries
Industries % of holdings value
Drug Manufacturers - General 29.8%
Biotechnology 23.8%
Medical Devices 13.8%
Medical Instruments & Supplies 7.5%
Diagnostics & Research 6.9%
Healthcare Plans 5.8%
Drug Manufacturers - Specialty & Generic 2.8%
Other (3) 6.1%
Unclassified 3.5%
Initiations 3 Value
Natera, Inc. NTRA 1.6% of portfolio $307K
Dianthus Therapeutics, Inc. DNTH 0.9% of portfolio $186K
Kardigan, Inc. KARD 0.5% of portfolio $96.3K
Increases 12 Change
UnitedHealth Group Incorporated UNH $272K → $1.13M 4.1x
Vertex Pharmaceuticals Incorporated VRTX $299K → $823K 2.3x
Quest Diagnostics Incorporated DGX $144K → $270K +52%
Spyre Therapeutics, Inc. SYRE $70.6K → $151K +76%
DexCom, Inc. DXCM $562K → $757K +9%
GALDERMA GROUP AG GALD $220K → $274K +27%
Agilent Technologies, Inc. A $556K → $689K +9%
Edwards Lifesciences Corporation EW $600K → $681K +8%
Cytokinetics, Incorporated CYTK $281K → $309K +19%
Structure Therapeutics Inc. GPCR $39.7K → $84.4K +82%
Praxis Precision Medicines, Inc. PRAX $111K → $142K +28%
BridgeBio Pharma, Inc. BBIO $147K → $185K +9%
Reductions 24 Change
Guardant Health, Inc. GH $1.07M → $787K −40%
Boston Scientific Corporation BSX $760K → $302K −60%
AstraZeneca AZN $974K → $396K −53%
Thermo Fisher Scientific Inc TMO $910K → $687K −40%
Eli Lilly and Company LLY $2.67M → $2.39M −15%
Johnson & Johnson JNJ $1.62M → $1.63M −15%
Hoya Corporation 7741 $710K → $400K −38%
argenx SE ARGX $818K → $812K −20%
Intuitive Surgical, Inc. ISRG $785K → $575K −17%
Xenon Pharmaceuticals Inc. XENE $272K → $179K −40%
CG Oncology, Inc. CGON $151K → $72.2K −61%
Lonza Group Ltd O6Z $563K → $550K −12%
Terminations 5 Change
Apogee Therapeutics, Inc. APGE was $396K −100%
Penumbra, Inc. PEN was $323K −100%
Ionis Pharmaceuticals, Inc. IONS was $276K −100%
Revolution Medicines, Inc. RVMD was $168K −100%
Insulet Corporation PODD was $57.7K −100%

Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Aug 31, 2026 (Form N-PORT) vs the portfolio of May 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

The Goldman Sachs Future Health Care Equity ETF (the "Fund") seeks long-term growth of capital.

Principal investment strategies

The Fund invests, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes (measured at the time of purchase) ("Net Assets") in equity investments in U.S. and non-U.S. health care companies. Goldman Sachs Asset Management, L.P. ("GSAM" or the "Investment Adviser") generally defines a health care company as a company in the health care sector. The Investment Adviser may use the classifications assigned by third parties but is not required to do so. The Fund seeks to achieve its investment objective by investing in health care companies that the Investment Adviser believes are driving innovation in health care, by developing either new treatments or new technologies, primarily in the fields of genomics, precision medicine, technology-enabled procedures and digital healthcare. The Investment Adviser seeks to identify companies at various growth stages, including dominant businesses with strong competitive advantages, companies that are early innovators and have developed new treatments or technologies, and companies that are enabling new treatments or technologies that have the potential to disrupt existing markets or serve existing markets more efficiently. Equity investments may include common stock, preferred stock, warrants and other rights to acquire stock, American depositary receipts ("ADRs"), European depositary receipts ("EDRs"), and global depositary receipts ("GDRs"), underlying funds (including exchange-traded funds ("ETFs")), and futures, forwards, options and other instruments with similar economic exposures. The Fund may invest in companies that only recently began to trade publicly. The Fund may invest in underlying ETFs, exchange-traded products ("ETPs") and/or money market funds, including those that currently exist or that may become available for investment in the future for which the Investment Adviser or an affiliate now or in the future acts as investment adviser or principal underwriter. The Fund may also invest in unaffiliated ETFs, ETPs and/or money market funds. 2 Summary Prospectus — Goldman Sachs Future Health Care Equity ETF The Fund generally intends to invest in companies that the Investment Adviser believes are aligned with key themes associated with innovation in health care, which include, but are not limited to, genomics, precision medicine, technology-enabled procedures, and digital healthcare (the "Key Themes"). The Key Themes currently are: Genomics: represents companies that, in the Investment Adviser's view, provide, invest in or help create products, services or technologies in areas including, but not limited to, sequencing, diagnostic testing and the genomics supply chain. Precision Medicine: represents companies that, in the Investment Adviser's view, provide, invest in or help create products, services or technologies in areas including, but not limited to, targeted oncology, gene/cell therapy and rare diseases. Technology-Enabled Procedures: represents companies that, in the Investment Adviser's view, provide, invest in or help create products, services or technologies in areas including, but not limited to, robotic surgery and minimally invasive procedures. Digital Healthcare: represents companies that, in the Investment Adviser's view, provide, invest in or help create products, services or technologies in areas including, but not limited to, connected devices, digital transformation, and online health. The Key Themes and related areas of investment may change over time at the sole discretion of the Investment Adviser without prior notice to shareholders. In addition, the Fund is permitted to make investments that are not aligned with the Key Themes. In selecting investments, the Investment Adviser will not seek to allocate a specified portion of the Fund's portfolio to each particular Key Theme, and the allocation of the Fund's investments across the Key Themes will vary over time in the Investment Adviser's sole discretion.

Management and Contact

Adviser
Goldman Sachs Asset Management, L.P.
Portfolio managers

Jenny Chang, Managing Director; and Raj Garigipati, Managing Director, have each managed the Fund since November 2021. 5 Summary Prospectus — Goldman Sachs Future Health Care Equity ETF

Phone
800-621-2550

Holdings as of Aug 31, 2026

41 lines, 38 linked, weights sum to 100.41% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
ELI LILLY & COMPANY LLY US5324571083 Equity 2,066 −351 12.19% $ 2.39M
JOHNSON & JOHNSON JNJ US4781601046 Equity 6,127 −1,077 8.31% $ 1.629M
MERCK & COMPANY INC MRK US58933Y1055 Equity 9,861 −212 7.44% $ 1.457M
UNITEDHEALTH GROUP INC UNH US91324P1021 Equity 2,912 +2,197 5.79% $ 1.134M
VERTEX PHARMACEUTICALS INC VRTX US92532F1003 Equity 1,511 +844 4.20% $ 822.77K
ARGENX SE ARGX US04016X1019 Equity 787 −192 4.14% $ 811.916K
GUARDANT HEALTH INC GH US40131M1099 Equity 4,952 −3,334 4.02% $ 787.467K
DEXCOM INC DXCM US2521311074 Equity 8,317 +696 3.86% $ 757.346K
AGILENT TECHNOLOGIES INC A US00846U1016 Equity 4,485 +380 3.51% $ 688.717K
THERMO FISHER SCIENTIFIC INC TMO US8835561023 Equity 1,114 −733 3.51% $ 687.449K
EDWARDS LIFESCIENCES CORP EW US28176E1082 Equity 7,509 +570 3.48% $ 681.442K
INTUITIVE SURGICAL INC ISRG US46120E6023 Equity 1,526 −323 2.93% $ 575.088K
LONZA GROUP AG LONN CH0013841017 Equity 771 −108 2.81% $ 550.23K
CENCORA INC COR US03073E1055 Equity 1,619 −131 2.67% $ 523.908K
ROIVANT SCIENCES LTD ROIV BMG762791017 Equity 14,044 −1,992 2.48% $ 486.484K
HOYA CORP 7741 JP3837800006 Equity 2,595 −1,578 2.04% $ 399.743K
ASTRAZENECA PLC AZN GB0009895292 Equity 2,440 −2,794 2.02% $ 395.986K
ROYALTY PHARMA PLC RPRX GB00BMVP7Y09 Equity 5,584 −786 1.75% $ 342.913K
METTLER-TOLEDO INTERNATIONAL INC MTD US5926881054 Equity 238 −33 1.71% $ 334.423K
REPLIGEN CORP RGEN US7599161095 Equity 1,789 −249 1.65% $ 323.773K
Goldman Sachs Trust
FTOXX US38141W3236 Money market 311,849.22 +23,860.64 1.59% $ 311.849K
CYTOKINETICS INC CYTK US23282W6057 Equity 4,355 +692 1.58% $ 308.813K
NATERA INC NTRA US6323071042 Equity 955 new +955 1.57% $ 307.472K
BOSTON SCIENTIFIC CORP BSX US1011371077 Equity 6,257 −9,483 1.54% $ 302.213K
GALDERMA GROUP AG
GALD CH1335392721 Equity 1,318 +284 1.40% $ 273.893K
QUEST DIAGNOSTICS INC DGX US74834L1008 Equity 1,125 +384 1.38% $ 270.338K
INSMED INC INSM US4576693075 Equity 1,823 −258 1.13% $ 222.078K
MADRIGAL PHARMACEUTICALS INC MDGL US5588681057 Equity 376 −54 1.04% $ 203.051K
DIANTHUS THERAPEUTICS INC DNTH US2528281080 Equity 1,761 new +1,761 0.95% $ 185.979K
BRIDGEBIO PHARMA INC BBIO US10806X1028 Equity 2,421 +207 0.95% $ 185.424K
XENON PHARMACEUTICALS INC XENE CA98420N1050 Equity 2,974 −2,003 0.91% $ 179.094K
SPYRE THERAPEUTICS INC SYRE US00773J2024 Equity 1,690 +730 0.77% $ 150.968K
DEFINIUM THERAPEUTICS INC DFTX CA24477V1058 Equity 3,695 −519 0.75% $ 146.765K
RHYTHM PHARMACEUTICALS INC RYTM US76243J1051 Equity 1,346 −192 0.73% $ 142.851K
PRAXIS PRECISION MEDICINES INC PRAX US74006W2070 Equity 406 +90 0.73% $ 142.222K
ALKERMES PLC ALKS IE00B56GVS15 Equity 2,367 −336 0.57% $ 111.225K
SARTORIUS STEDIM BIOTECH SA DIM FR0013154002 Equity 467 −66 0.54% $ 106.324K
KARDIGAN INC KARD US4859251013 Equity 4,775 new +4,775 0.49% $ 96.264K
GOLDMAN SACHS FINANCIAL SQUARE FUNDS PRIME OBLIGATIONS FUND
FGTXX Money market 94,704.09 new +94,704.09 0.48% $ 94.704K
STRUCTURE THERAPEUTICS INC GPCR US86366E1064 Equity 1,838 +830 0.43% $ 84.383K
CG ONCOLOGY INC CGON US1569441009 Equity 960 −1,472 0.37% $ 72.154K

Trades May 31, 2026 to Aug 31, 2026

Holding Ticker Action Before After Change Value
UNITEDHEALTH GROUP INC UNH Bought 715 2,912 +2,197 $ 855.534K
GUARDANT HEALTH INC GH Sold 8,286 4,952 −3,334 $ -530.173K
VERTEX PHARMACEUTICALS INC VRTX Bought 667 1,511 +844 $ 459.575K
BOSTON SCIENTIFIC CORP BSX Sold 15,740 6,257 −9,483 $ -458.029K
ASTRAZENECA PLC AZN Sold 5,234 2,440 −2,794 $ -453.436K
THERMO FISHER SCIENTIFIC INC TMO Sold 1,847 1,114 −733 $ -452.334K
ELI LILLY & COMPANY LLY Sold 2,417 2,066 −351 $ -406.012K
APOGEE THERAPEUTICS INC APGE Closed 4,823 — −4,823 $ -396.161K
PENUMBRA INC PEN Closed 1,015 — −1,015 $ -323.075K
NATERA INC NTRA New — 955 +955 $ 307.472K
JOHNSON & JOHNSON JNJ Sold 7,204 6,127 −1,077 $ -286.32K
IONIS PHARMACEUTICALS INC IONS Closed 3,614 — −3,614 $ -276.471K
HOYA CORP 7741 Sold 4,173 2,595 −1,578 $ -243.081K
ARGENX SE ARGX Sold 979 787 −192 $ -198.079K
DIANTHUS THERAPEUTICS INC DNTH New — 1,761 +1,761 $ 185.979K
REVOLUTION MEDICINES INC RVMD Closed 1,069 — −1,069 $ -168.346K
INTUITIVE SURGICAL INC ISRG Sold 1,849 1,526 −323 $ -121.726K
XENON PHARMACEUTICALS INC XENE Sold 4,977 2,974 −2,003 $ -120.621K
CG ONCOLOGY INC CGON Sold 2,432 960 −1,472 $ -110.636K
KARDIGAN INC KARD New — 4,775 +4,775 $ 96.264K
QUEST DIAGNOSTICS INC DGX Bought 741 1,125 +384 $ 92.275K
LONZA GROUP AG LONN Sold 879 771 −108 $ -77.075K
ROIVANT SCIENCES LTD ROIV Sold 16,036 14,044 −1,992 $ -69.003K
SPYRE THERAPEUTICS INC SYRE Bought 960 1,690 +730 $ 65.211K
DEXCOM INC DXCM Bought 7,621 8,317 +696 $ 63.378K
GALDERMA GROUP AG
GALD Bought 1,034 1,318 +284 $ 59.018K
AGILENT TECHNOLOGIES INC A Bought 4,105 4,485 +380 $ 58.353K
INSULET CORP PODD Closed 398 — −398 $ -57.686K
EDWARDS LIFESCIENCES CORP EW Bought 6,939 7,509 +570 $ 51.728K
CYTOKINETICS INC CYTK Bought 3,663 4,355 +692 $ 49.07K
ROYALTY PHARMA PLC RPRX Sold 6,370 5,584 −786 $ -48.268K
METTLER-TOLEDO INTERNATIONAL INC MTD Sold 271 238 −33 $ -46.37K
REPLIGEN CORP RGEN Sold 2,038 1,789 −249 $ -45.064K
CENCORA INC COR Sold 1,750 1,619 −131 $ -42.392K
STRUCTURE THERAPEUTICS INC GPCR Bought 1,008 1,838 +830 $ 38.105K
PRAXIS PRECISION MEDICINES INC PRAX Bought 316 406 +90 $ 31.527K
INSMED INC INSM Sold 2,081 1,823 −258 $ -31.43K
MERCK & COMPANY INC MRK Sold 10,073 9,861 −212 $ -31.325K
MADRIGAL PHARMACEUTICALS INC MDGL Sold 430 376 −54 $ -29.162K
DEFINIUM THERAPEUTICS INC DFTX Sold 4,214 3,695 −519 $ -20.615K
RHYTHM PHARMACEUTICALS INC RYTM Sold 1,538 1,346 −192 $ -20.377K
BRIDGEBIO PHARMA INC BBIO Bought 2,214 2,421 +207 $ 15.854K
ALKERMES PLC ALKS Sold 2,703 2,367 −336 $ -15.789K
SARTORIUS STEDIM BIOTECH SA DIM Sold 533 467 −66 $ -15.026K

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up